NYSE · Healthcare · Medical Devices

Edwards Lifesciences Corporation (EW)

As of Nov 11, 1:49 PM ET, Edwards Lifesciences (EW) last traded at $104.98, up 0.93% on the day. Its TickerHum research score is 66/100 (above average). It reported revenue of $6.67B for the twelve months ending 2026-09-30, up 13.4% year over year, with a 21.6% operating margin.

Ratings

Valuation: 34/100 — Strongest input: price / sales (ttm) 9.0x. Weakest: price / earnings (ttm) 59.3x.
Growth: 30/100 — Strongest input: revenue growth (ttm, yoy) +13.4 %. Weakest: diluted eps growth (ttm, yoy) -24.7 %.
Profitability: 69/100 — Strongest input: gross margin 78.0 %. Weakest: return on equity 9.4 %.
Financial health: 99/100 — Strongest input: current ratio 4.60. Weakest: long-term debt / equity 0.06.
Momentum: 80/100 — Strongest input: price vs 200-day average +22.0 %. Weakest: 1-year return +22.7 %.
Attention: 50/100 — Strongest input: headlines in the last 7 days 54. Weakest: volume vs 3-month average 0.4x.
Risk resilience: 85/100 — Strongest input: max drawdown (1y) -13.2 %. Weakest: annualised volatility (1y) 25.5 %.
Data confidence: 100/100 — Based on inputs available 100 %, quote age (hours) 0 h, latest financial period age (days) 43 d.

Reported fundamentals

Metric	Value	Period
Revenue	$6.67B	TTM ending 2026-09-30 · 10-Q
Revenue growth	13.4%	TTM ending 2026-09-30 · 10-Q
Net income	$1.02B	TTM ending 2026-09-30 · 10-Q
Diluted EPS	$1.77	TTM ending 2026-09-30 · 10-Q
Gross margin	78.0%	TTM ending 2026-09-30 · 10-Q
Operating margin	21.6%	TTM ending 2026-09-30 · 10-Q
Net margin	15.3%	TTM ending 2026-09-30 · 10-Q
Free cash flow	$1.42B	TTM ending 2026-09-30 · 10-Q
Cash	$3.11B	as of 2026-09-30 · 10-Q
Long-term debt	$598.8M	as of 2026-09-30 · 10-Q
Debt / equity	0.06	as of 2026-09-30 · 10-Q

Source: SEC EDGAR XBRL company facts (CIK 0001099800).

Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.